Floatz logo

Ruxolitinib

Acquired Polycythemia Vera

University of WashingtonSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Acquired Polycythemia Vera cohort.

Asset / SponsorPhaseRating
Tacrolimus
Thomas Jefferson University
Phase 2BB
Pegylated-Proline-Interferon Alpha-2B
AOP Orphan Pharmaceuticals AG
Phase 3BB
Fludarabine
Thomas Jefferson University
Phase 2BB
Cyclophosphamide
Thomas Jefferson University
Phase 2BB
Therapeutic Allogeneic Lymphocytes
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB

View all 36 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BB
Indicative · Phase 4
70 / 100
View asset →
graft versus host diseaseActive
BB
Indicative · Phase 4
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →